Xcision Medical Systems, LLC has joined forces with the Canadian Nuclear Isotope Council (CNIC).
Xcision is a medical technology company that develops advanced stereotactic radiotherapy solutions with the potential to significantly improve the quality of cancer care, as well as the lives of patients. The CNIC’s mandate is to ensure that Canada remains a world leader in the production of medical and industrial radioisotopes by raising awareness and supporting long-term policies at the domestic and international levels.
Together, the organizations hope to extend the benefits of radiation oncology to more patients and enable precision, non-invasive treatments that allow patients to live fuller lives, with less discomfort after receiving a cancer diagnosis.
Xcision’s initial focus is on breast cancer, using stereotactic radiotherapy to deliver focused radiation to a partial volume of the breast in conjunction with breast conserving treatment. The company’s first product, GammaPod™, is a new stereotactic radiotherapy system optimized for the treatment of breast cancer. The GammaPod delivers treatments using a multisource Cobalt-60 system, which continuously rotates during treatment, creating thousands of beam angles. Individual beams converge to create an intense focal spot, delivering the full dose to the target while sparing surrounding healthy tissue.
“Continued production of Cobalt-60 in Ontario and Canadian isotope leadership and development are essential to our success,” said Professor Cedric Yu, Chief Executive Officer of Xcision. “Technologies like the GammaPod™ have the potential to revolutionize the management of localized breast cancer and create genuine value for patients, providers and payers like the Canadian government. By partnering with the CNIC, we can address the growing global demand for higher quality, more efficient and cost-effective cancer care that improves patient satisfaction and convenience.”
James Scongack, Chair of the CNIC, said through leadership in nuclear science, Ontario has made important contributions in energy, medicine, manufacturing, and health care.
“The GammaPod is a fascinating technology with the potential to shorten the course of treatment, thereby increasing patient convenience and the capacity to treat more patients faster, which can reduce wait times,” Scongack said. “The time is now to treat patients with a radiotherapy tool that has been painstakingly optimized to expertly treat their specific type of cancer. Every patient is unique and deserves specialized care.”
The CNIC works to maintain Canada’s role as a leader in this field by encouraging innovation and investment in isotope research and development by industries and government.
About Xcision Medical Systems, LLC
Xcision Medical Systems, LLC is a medical technology company developing advanced stereotactic radiotherapy solutions with the potential to significantly improve the quality of cancer care as well as the lives of patients and their loved ones. The company’s technology is designed to extend the benefits of radiation oncology to more patients and enable precision non-invasive treatments that allow patients to return to living fuller lives more quickly with less discomfort after receiving a cancer diagnosis.
Steve Rubenstein
443.681.7463
steve.rubenstein@xcision.com